AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Core Insights - AN2 Therapeutics has voluntarily paused Phase 3 enrollment in the EBO-301 clinical trial for epetraborole due to lower than expected efficacy observed in a blinded aggregate analysis of the ongoing Phase 2 study [1][2][3] - The Phase 2 part of the trial, which completed enrollment in September 2023 with 80 patients, is intended to inform the Phase 3 part, which has enrolled nearly 100 patients to date [2][3] - The company plans to provide further details regarding the trial in the second quarter of 2024 following the completion of data analysis [3] Company Overview - AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs [4] - The company's lead candidate, epetraborole, is being studied as a once-daily oral treatment for nontuberculous mycobacteria (NTM) lung disease, which is a rare and progressive infectious disease [4]